Loading the latest PSX data…
Loading the latest PSX data…
Citi Pharma Ltd.Shariah-compliantKSE-100
+0.37 (+0.58%) today
Live, checked 0s agoThe Citi Pharma share price was Rs 63.79 (+0.58%) at the last PSX update (Nov 16, 2026 10:34 AM). CPHL is a pharmaceuticals stock in the KSE-100 index with a market value of Rs 14.6bn.
Last session's range13 Nov 2026
62.5086% up the range64.00
52-week range
56.1120% up the range93.99
Price limits (circuit breakers)
57.2052% up the range69.91
CPHL ranks better than 32% of the 304 liquid PSX stocks we score. Each factor is a 0-100 rank (value is ranked half within pharmaceuticals). Education only, not a buy or sell signal.
−19.4% over 6M
Daily bars from PSX's end-of-day market summary; today's candle is provisional, from the live price (no volume until the close). Prices before a bonus issue, right issue or split are adjusted so the chart stays continuous; cash dividends are not taken out.
Full-screen CPHL chart with levelsDownload CPHL price history (CSV)Compare CPHL with GLAXO
From daily closes to 2026-11-13. A description of the trend, not a forecast.
Trend reading
Downtrend
Down1 up · 5 down signalsUp
| S2 | S1 | Pivot | R1 | R2 |
|---|---|---|---|---|
| 61.81 | 62.61 | 63.31 | 64.11 | 64.81 |
+77.8% over 5 years
Monthly closing prices from the PSX Data Portal, since 2021. Earlier prices are adjusted for bonus shares and splits (×1.10 shares, 2021-10) so the line shows the value of one original share.
| Announced | Period | Payout | Profit after tax | EPS (Rs) | Books close |
|---|---|---|---|---|---|
| 2 Nov 15:54 | 1st quarter to 30 Sept | None | – | 1.09 | – |
| 2 Nov 15:53 | 1st quarter to 30 Sept | None | Rs 233.2m | 1.02 | – |
| 5 Oct 15:15 | Full year to 30 Jun | None | – | 3.46 | – |
| 5 Oct 15:14 | Full year to 30 Jun | None | Rs 782.6m | 3.43 | 22 Oct – 28 Oct |
| 28 Aug 16:29 | – to – | None | – | – | 12 Sept – 18 Sept |
| 15 Jun 16:01 | – to – | None | – | – | 2 Jul – 8 Jul |
| 30 Apr 15:15 | 9 months to 31 Mar | None | Rs 883.4m | 3.87 | – |
| Measure | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Sales growth | +6.5% | +6.0% | +0.1% | – |
| Profit growth | −12.3% | +7.0% | +26.7% | – |
| EPS growth | −12.1% | +6.8% | +26.7% | – |
| Net margin | 5.6% | 6.8% | 6.7% | 5.3% |
| Measure | Q1 2027 | Q3 2026 | Q2 2026 | Q1 2026 |
|---|---|---|---|---|
| Sales growth | −0.2% | – | – | – |
| Profit growth | +14.5% | – | – | – |
| EPS growth | +14.6% | – | – | – |
| Net margin | 6.9% | 8.9% | 9.3% | 6.0% |
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Sales | Rs 14.0bn | Rs 13.2bn | Rs 12.4bn | Rs 12.4bn |
| Profit after tax | Rs 783m | Rs 892m | Rs 833m | Rs 658m |
| Earnings per share (Rs) | 3.43 | 3.90 | 3.65 | 2.88 |
| Line item | Q1 2027 | Q3 2026 | Q2 2026 | Q1 2026 |
|---|---|---|---|---|
| Sales | Rs 3.4bn | Rs 3.1bn | Rs 4.3bn | Rs 3.4bn |
| Profit after tax | Rs 233m | Rs 275m | Rs 404m | Rs 204m |
| Earnings per share (Rs) | 1.02 | 1.21 | 1.77 | 0.89 |
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Gross margin | 17.5% | 15.3% | 12.8% | 12.2% |
| Net margin | 5.6% | 6.8% | 6.7% | 5.3% |
| EPS growth | -12.1% | 6.9% | 26.7% | – |
| PEG | -1.88 | 3.14 | 0.29 | – |
Rupee amounts from PSX filings (thousands converted to Rs m/bn). Data by Capital Stake via the PSX Data Portal; standardised, so it can differ from the annual report. Latest quarter (Q1 2027) EPS rose 14.6% from the same quarter a year earlier.
| Measure | CPHL | Sector median | Reading |
|---|---|---|---|
| P/E | 17.9 | 12.3 | Dearer than peers |
| Dividend yield | – | 5.1% | – |
| Net margin | 5.6% | 9.4% | Below peers |
| EPS growth | −12.1% | +34.5% | Below peers |
| 1-year return | −22.6% | −14.4% | Below peers |
Sector P/E check. At the sector's median P/E of 12.3, last year's EPS of Rs 3.43 would price CPHL at about Rs 42.23 (−34% from today). A rough yardstick only: sectors hold very different businesses, and the market prices future profits, not last year's.
Estimate a fair value for CPHL (Graham, Lynch, DCF)CPHL pivot levels
Ratios as published on the PSX Data Portal (standardised by Capital Stake), latest financial year on the right.
Work out your CPHL dividend income after tax
PSX quotes payouts as a percentage of face value; cash per share assumes the usual Rs 10 face value. You get the dividend if you own the shares before the books close.
Market value
9th of 18
Rs 14.6bn
P/E (cheapest first)
9th of 13
17.9
1-year return
12th of 15
-22.6%
EPS growth
14th of 15
-12.1%
Net margin
12th of 16
5.6%
danioPSX score
11th of 13
32/100
| GLAXOGlaxoSmithKline Pakistan Limited | Rs 108.3bn | +1.08% | 9.9 | 6.1% | −14.9% | 88 |
| ABOTAbbott Laboratories (Pakistan) Limited | Rs 99.6bn | +1.70% | 10.7 | 4.4% | −6.9% | 82 |
| HALEONHaleon Pakistan Limited | Rs 81.2bn | −0.45% | 12.5 | 3.6% | −14.8% | 67 |
| HINOONHighnoon Laboratories Limited | Rs 51.0bn | +0.40% | 12.4 | 5.4% | −14.0% | 79 |
| SEARLThe Searle Company Limited | Rs 47.5bn | +1.87% | 12.2 | – | −24.6% | 53 |
| AGPAGP Limited | Rs 43.9bn | +0.32% | 24.5 | 5.1% | −16.1% | 50 |
| HPLHoechst Pakistan Limited | Rs 38.8bn | +0.73% | 11.1 | 6.9% | −2.3% | – |
| FEROZFerozsons Laboratories Limited | Rs 16.1bn | +1.98% | 23.4 | 1.6% | −7.1% | 39 |
| CPHLThis stock · Citi Pharma Ltd. | Rs 14.6bn | +0.58% | 17.9 | – | −22.6% | 32 |
| GSKCHGlaxoSmithKline Consumer Healthcare | Rs 14.1bn | −3.13% | – | – | – | – |
| MACTERMacter International Limited | Rs 12.3bn | +1.87% | 3.8 | – | −26.7% | 52 |
| BFBIOBF Biosciences Limited | Rs 12.0bn | +0.55% | 18.3 | – | −10.8% | 48 |
| SAPLSanofi-Aventis Pakistan Limited | Rs 8.4bn | 0.00% | – | – | – | – |
| OTSUOtsuka Pakistan Limited | Rs 5.4bn | +1.43% | 11.1 | – | +33.5% | 63 |
| LIVENLiven Pharma Limited | Rs 4.9bn | +10.00% | – | – | −18.9% | 9 |
Swipe the table sideways for more columns.
| Date | Who | Trade | Shares | Price | Value | Holding after | Notice |
|---|---|---|---|---|---|---|---|
| 5 Aug 26 | Rizwan AhmadExecutive Director | BoughtReady | 2,000,000 | 74.66 | Rs 149.3m | 56,029,75224.52% | Notice |
Read automatically (OCR) from the disclosure images companies file with PSX under Regulation 5.6.1(d). A digit can be misread, so check the original notice before relying on a figure. Value = shares × price. Not investment advice. All PSX insider trades
Citi Pharma Limited was incorporated as a private limited company in Pakistan under the Repealed Companies Ordinance, 1984 on October 08, 2012. The principal activity of the company is manufacturing and sale of pharmaceuticals, medical chemicals and botanical products. The company was converted into public unlisted company with effect from October 13, 2020. The Company was listed on Pakistan Stock Exchange on July 09, 2021.
Where the price sits in its 52-week range
Low 56.1120% of the way upHigh 93.99
Data: PSX Data Portal (Nov 16, 2026 10:34 AM); company data refreshed 16 Nov; daily bars from PSX market summaries; five-year record from danioPSX research. Logos are trademarks of their owners. Not a recommendation to buy or sell CPHL. Official PSX page for CPHL